Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing

Journal of Clinical Investigation

Volumn 120, Issue 3, 2010, Pages 871-882

  Bonnart, Chrystelle ^a,b   Deraison, Céline ^a,b   Lacroix, Matthieu ^a,b   Uchida, Yoshikazu ^c   Besson, Céline ^a,b   Robin, Aurélie ^a,b   Briot, Anaïs ^a,b   Gonthier, Marie ^b,d   Lamant, Laurence ^e   Dubus, Pierre ^f   Monsarrat, Bernard ^b,d   Hovnanian, Alain ^a,g,h  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTASE II; FILAGGRIN; KERATOHYALIN; SERINE PROTEINASE; SKIN LIPID; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEHYDRATION; ENZYME LOCALIZATION; EPIDERMIS; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOUSE; NETHERTON DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; SKIN BARRIER DEFECT; SKIN FUNCTION; TRANSGENIC MOUSE; WATER LOSS; ZYMOGRAPHY;

ANIMALS; CYTOPLASMIC GRANULES; EPIDERMIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTERMEDIATE FILAMENT PROTEINS; KERATINS; LIPID METABOLISM; MICE; MICE, TRANSGENIC; NETHERTON SYNDROME; SERINE ENDOPEPTIDASES;

EID: 77949752021     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41440     Document Type: Article

References (55)

1. Fuchs E. Scratching the surface of skin development. Nature. 2007;445(7130):834-842.
2. Sandilands A, Sutherland C, Irvine AD, Irwin McLean WH. Filaggrin in the fronline: role in skin barrier function and disease. J Cell Sci. 2009;122(Pt 9):1285-1294.
3. Swartzendruber DC, Wertz PW, Kitko DJ, Madison KC, Downing DT. Molecular models of the intercellular lipid lamellae in mammalian stratum corneum. J Invest Dermatol. 1989;92(2):251-257.
4. Uchida Y, et al. Epidermal sphingomyelins are precursors for selected stratum corneum ceramides. J Lipid Res. 2000;41(12):2071-2082.
5. Hart TC, et al. Mutations of the cathepsin C gene are responsible for Papillon-Lefevre syndrome. J Med Genet. 1999;36(12):881-887.
6. Basel-Vanagaite L, et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet. 2007;80(3):467-477.
7. Chavanas S, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25(2):141-142.
8. Comel M. Ichtyosis Linearis circumflexa. Dermatologica. 1949;98(3):133-136.
9. Netherton EW. A unique case of Trichorrexis Invaginata. Arch Dermatol. 1958;78:483-487.
10. Ong C, and Harper J. Netherton's Syndrome. In: Harper J, Oranje A, Prose N, eds. Textbook of Pediatric Dermatology. Oxford, United Kingdom: Wiley/ Blackwell. 2006:1359-1366.
11. Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr Dermatol. 1996;13(3):183-199.
12. Bitoun E, et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol. 2002;118(2):352-361.
13. Sprecher E, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol. 2001;117(2):179-187.
14. Raghunath M, et al. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol. 2004;123(3):474-483.
15. Deraison C, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell. 2007;18(9):3607-3619.
16. Descargues P, et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet. 2005;37(1):56-65.
17. Largman C, Brodrick JW, Geokas MC, Johnson JH, Fassett M. Demonstration of a pancreatic proelastase 2-alpha 1-protease inhibitor complex in normal human plasma. Am J Physiol. 1980;238(3):G177-G182.
18. Egelrud T, et al. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br J Dermatol. 2005;153(6):1200-1203.
19. Borgono CA, et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem. 2007;282(6):3640-3652.
20. Schechter NM, et al. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lymphoepithelial Kazal-type inhibitor (LEKTI). Biol Chem. 2005;386(11):1173-1184.
21. Wingens M, et al. Induction of SLPI (ALP/HUSII) in epidermal keratinocytes. J Invest Dermatol. 1998;111(6):996-1002.
22. Alkemade JA, et al. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci. 1994;107(Pt 8):2335-2342.
23. Carroll JM, Albers KM, Garlick JA, Harrington R, Taichman LB. Tissue- and stratum-specific expression of the human involucrin promoter in transgenic mice. Proc Natl Acad Sci U S A. 1993;90(21):10270-10274.
24. Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Arch Dermatol. 1999;135(7):823-832.
25. Descargues P, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsinand chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol. 2006;126(7):1622-1632.
26. Ishida-Yamamoto A, Hashimoto Y, Manabe M, O'Guin WM, Dale BA, Iizuka H. Distinctive expression of filaggrin and trichohyalin during various pathways of epithelial differentiation. Br J Dermatol. 1997;137(1):9-16.
27. Kawashima I, Tani T, Shimoda K, Takiguchi Y. Characterization of pancreatic elastase II cDNAs: two elastase II mRNAs are expressed in human pancreas. DNA. 1987;6(2):163-172.
28. Toulza E, et al. Large-scale identification of human genes implicated in epidermal barrier function. Genome Biol. 2007;8(6):R107.
29. Banks EB, Crish JF, Welter JF, Eckert RL. Characterization of human involucrin promoter distal regulatory region transcriptional activator elements-a role for Sp1 and AP1 binding sites. Biochem J. 1998;331(Pt 1):61-68.
30. Oh HS, Smart RC. Expression of CCAAT/enhancer binding proteins (C/EBP) is associated with squamous differentiation in epidermis and isolated primary keratinocytes and is altered in skin neoplasms. J Invest Dermatol. 1998;110(6):939-945.
31. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A. 1986;83(18):6692-6696.
32. Schalkwijk J, de Roo C, de Jongh GJ. Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim Biophys Acta. 1991;1096(2):148-154.
33. Shimomura Y, Sato N, Kariya N, Takatsuka S, Ito M. Netherton syndrome in two Japanese siblings with a novel mutation in the SPINK5 gene: immunohistochemical studies of LEKTI and other epidermal molecules. Br J Dermatol. 2005;153(5):1026-1030.
34. Denecker G, et al. Caspase-14 protects against epidermal UVB photodamage and water loss. Nat Cell Biol. 2007;9(6):666-674.
35. Resing KA, Thulin C, Whiting K, al-Alawi N, Mostad S. Characterization of profilaggrin endoproteinase 1. A regulated cytoplasmic endoproteinase of epidermis. J Biol Chem. 1995;270(47):28193-28198.
36. Yamazaki M, et al. Cytoplasmic processing of human profilaggrin by active mu-calpain. Biochem Biophys Res Commun. 1997;235(3):652-656.
37. Pearton DJ, Nirunsuksiri W, Rehemtulla A, Lewis SP, Presland RB, Dale BA. Proprotein convertase expression and localization in epidermis: evidence for multiple roles and substrates. Exp Dermatol. 2001;10(3):193-203.
38. List K, et al. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/ MT-SP1. J Cell Biol. 2003;163(4):901-910.
39. Leyvraz C, et al. The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J Cell Biol. 2005;170(3):487-496.
40. Presland RB, Boggess D, Lewis SP, Hull C, Fleckman P, Sundberg JP. Loss of normal profilaggrin and filaggrin in flaky tail (ft/ft) mice: an animal model for the filaggrin-deficient skin disease ichthyosis vulgaris. J Invest Dermatol. 2000;115(6):1072-1081.
41. Smith FJ, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006;38(3):337-342.
42. Palmer CN, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.
43. Hachem JP, et al. Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol. 2006;126(9):2074-2086.
44. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol. 1994;30(4):535-546.
45. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest. 1992;90(2):482-487.
46. Briot A, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135-1147.
47. Hazuda DJ, Strickler J, Kueppers F, Simon PL, Young PR. Processing of precursor interleukin 1 beta and inflammatory disease. J Biol Chem. 1990;265(11):6318-6322.
48. Bieberich E. Integration of glycosphingolipid metabolism and cell-fate decisions in cancer and stem cells: review and hypothesis. Glycoconj J. 2004;21(6):315-327.
49. Teichgraber V, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med. 2008;14(4):382-391.
50. Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme: a proteinase that may be involved in desquamation. J Invest Dermatol. 1993;101(2):200-204.
51. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 1975;6(3):331-343.
52. Watt FM, Boukamp P, Hornung J, Fusenig NE. Effect of growth environment on spatial expression of involucrin by human epidermal keratinocytes. Arch Dermatol Res. 1987;279(5):335-340.
53. Carroll JM, Taichman LB. Characterization of the human involucrin promoter using a transient beta-galactosidase assay. J Cell Sci. 1992; 103(Pt 4):925-930.
54. Talreja P, Kleene NK, Pickens WL, Wang TF, Kasting GB. Visualization of the lipid barrier and measurement of lipid pathlength in human stratum corneum. AAPS PharmSci. 2001;3:E13.
55. Wertz PW, Madison KC, Downing DT. Covalently bound lipids of human stratum corneum. J Invest Dermatol. 1989;92(1):109-111.